Each year, an estimated 7.9 million babies worldwide are born with birth defects, many of which appear healthy at birth and come from families with no history of the disorder. Many a‑ected babies are not identified until the appearance of severe and often irreversible symptoms later in life. The NOVA™ Newborn Genetic Test is a screening test that determines a baby’s risk for 50 inherited disorders, as well as providing personalized genetic information on the likely response of 20 pediatric drugs.
Utilizing Next Generation Sequencing technology and with access to BGI’s industry leading genetics bioinformatics software, the NOVA™ Newborn Genetic Test off‑ers one of the most comprehensive and accurate newborn screening tests on the market and enables healthcare providers to achieve early detection, referral and treatment of all babies identified as at high risk of the disorders screened for.
444 8 732